Cell Microarrays for High Throughput RNAi

用于高通量 RNAi 的细胞微阵列

• 批准号: 6694273
• 负责人: Jiwu Wang
• 金额: $ 9.95万
• 依托单位: ALLELE BIOTECHNOLOGY AND PHARMACEUTICALS
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-09-17 至 2004-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6694273
• 关键词: RNA; biotechnology; drug screening /evaluation; gene induction /repression; genetic screening; high throughput technology; microarray technology; reporter genes; technology /technique development; tissue /cell culture; transfection

DESCRIPTION (provided by applicant): The goal of this proposal is to further develop and adapt our existing DNA-based RNAi technology to a cell microarray format for high throughput gene function studies and potential drug screening efforts. The principle of arrays of living cells for "reverse transfection" has been established and applied to identifying cDNAs involved in cellular physiology changes. We will first utilize the published cell microarray method for our DNA-based RNAi system to prove the principle of microarrays of RNAi (MAR). We will then use the method to screen for genes the silencing of which will alter the expression of a reporter gene. This high throughput format of RNAi will impact the gene analysis and drug screening fields tremendously. Once we have developed this technology, we plan to take advantage of our strong collaborations and high market demand to distribute our RNAi systems throughout the biomedical field.

描述（由申请人提供）：本提案的目标是进一步开发和调整我们现有的基于DNA的RNAi技术，使其适用于高通量基因功能研究和潜在药物筛选工作的细胞微阵列格式。活细胞阵列“反向转染”的原理已经建立并应用于鉴定参与细胞生理变化的cDNA。我们将首先利用已发表的细胞微阵列方法为我们的基于DNA的RNAi系统，以证明RNAi（MAR）的微阵列的原理。然后，我们将使用该方法来筛选基因，其沉默将改变报告基因的表达。这种高通量的RNAi形式将极大地影响基因分析和药物筛选领域。一旦我们开发出这项技术，我们计划利用我们强大的合作和高市场需求，将我们的RNAi系统推广到整个生物医学领域。